Performance of the digene LQ, RH and PS HPVs genotyping systems on clinical samples and comparison with HC2 and PCR-based Linear Array

Infectious Agents and Cancer

Volumn 6, Issue 1, 2011, Pages

  Godínez, Jose M ^a   Tous, Sara ^a   Baixeras, Nuria ^b   Moreno Crespi, Judith ^c   Alejo, María ^d   Lejeune, Marylène ^e   Bravo, Ignacio G ^a   Bosch, F Xavier ^a   De Sanjosé, Silvia ^a,f  

^a L'Hospitalet de Llobregat   (Spain)

^b HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^c HOSPITAL JOSEP TRUETA   (Spain)

^d HOSPITAL GENERAL DE CATALUNYA   (Spain)

^e UNIVERSITAT ROVIRA I VIRGILI   (Spain)

^f NONE   (Spain)

Author keywords

cervical cancer screening; genotyping; HPV; Papillomaviruses

Indexed keywords

ADULT; ARTICLE; BIOTECHNOLOGY; CANCER SCREENING; CLINICAL ASSESSMENT; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; GENOTYPE; HC2 TECHNOLOGY; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 45; LABORATORY; LINEAR ARRAY TECHNOLOGY; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PAPILLOMAVIRUS INFECTION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SEROPREVALENCE; SEROTYPE; TUMOR GENE; UTERINE CERVIX; UTERINE CERVIX CANCER; UTERINE CERVIX CYTOLOGY; VIRUS DETECTION; VIRUS STRAIN; WART VIRUS;

EID: 81255209562     PISSN: None     EISSN: 17509378     Source Type: Journal    
DOI: 10.1186/1750-9378-6-23     Document Type: Article

References (36)

1. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Mũoz N, J Pathol 1999 189 1 12 9 10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F 10451482 (Pubitemid 29406813)
2. Last access. 2011 http://www.who.int/hpvcentre/en/
3. Human papillomavirus genotype distribution in external acuminata condylomata: a Large French National Study (EDiTH IV). Aubin F, Prétet JL, Jacquard AC, Saunier M, Carcopino X, Jaroud F, Pradat P, Soubeyrand B, Leocmach Y, Mougin C, Riethmuller D, EDiTH Study Group, Clin Infect Dis 2008 47 5 610 5 10.1086/590560 18637758
4. Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta-analysis. De Vuyst H, Clifford GM, Nascimento MC, Madeleine MM, Franceschi S, Int J Cancer 2009 124 7 1626 36 10.1002/ijc.24116 19115209
5. Human papillomavirus prevalence and type distribution in penile carcinoma. Miralles-Guri C, Bruni L, Cubilla AL, Castellsagué X, Bosch FX, de Sanjosé S, J Clin Pathol 2009 62 10 870 8 10.1136/jcp.2008.063149 19706632
6. Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments. Bernard HU, Burk RD, Chen Z, van Doorslaer K, Hausen H, de Villiers EM, Virology 2010 401 1 70 9 10.1016/j.virol.2010.02.002 20206957
7. International Agency for Research on Cancer Multicenter Cervical Cancer Study Group Epidemiologic classification of human papillomavirus types associated with cervical cancer. Mũoz N, Bosch FX, de Sanjosé S, Herrero R, Castellsagué X, Shah KV, Snijders PJ, Meijer CJ, N Engl J Med 2003 348 6 518 27 10.1056/NEJMoa021641 12571259 (Pubitemid 36159887)
8. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. de Sanjosé S, Quint WG, Alemany L, Geraets DT, Klaustermeier JE, Lloveras B, Tous S, Felix A, Bravo LE, Shin HR, Vallejos CS, de Ruiz PA, Lima MA, Guimera N, Clavero O, Alejo M, Llombart-Bosch A, Cheng-Yang C, Tatti SA, Kasamatsu E, Iljazovic E, Odida M, Prado R, Seoud M, Grce M, Usubutun A, Jain A, Suarez GA, Lombardi LE, Banjo A, Menéndez C, Domingo EJ, Velasco J, Nessa A, Chichareon SC, Qiao YL, Lerma E, Garland SM, Sasagawa T, Ferrera A, Hammouda D, Mariani L, Pelayo A, Steiner I, Oliva E, Meijer CJ, Al-Jassar WF, Cruz E, Wright TC, Puras A, Llave CL, Tzardi M, Agorastos T, Garcia-Barriola V, Clavel C, Ordi J, Andújar M, Castellsagué X, Sánchez GI, Nowakowski AM, Bornstein J, Mũoz N, Bosch FX, Retrospective International Survey and HPV Time Trends Study Group, Lancet Oncol 2010 11 11 1048 56 10.1016/S1470-2045(10)70230-8 20952254
9. Chapter 4: Burden and management of non-cancerous HPV-related conditions: HPV-6/11 disease. Lacey CJ, Lowndes CM, Shah KV, Vaccine 2006 24 Suppl 3 3/35 41
10. Effect of screening on incidence of and mortality from cancer of cervix in England: evaluation based on routinely collected statistics. Quinn M, Babb P, Jones J, Allen E, BMJ 1999 318 7188 904 8 10.1136/bmj.318.7188.904 10102852 (Pubitemid 29191925)
11. Cervical HPV infection and neoplasia in a large population-based prospective study: the Manchester cohort. Peto J, Gilham C, Deacon J, Taylor C, Evans C, Binns W, Haywood M, Elanko N, Coleman D, Yule R, Desai M, Br J Cancer 2004 91 5 942 53 15292939 (Pubitemid 39273789)
12. Comparison of two PCR-based human papillomavirus genotyping methods. Castle PE, Porras C, Quint WG, Rodriguez AC, Schiffman M, Gravitt PE, González P, Katki HA, Silva S, Freer E, Van Doorn LJ, Jiménez S, Herrero R, Hildesheim A, CVT Group, J Clin Microbiol 2008 46 10 3437 45 10.1128/JCM.00620-08 18716224
13. Clinical utility of HPV genotyping. Meijer CJ, Snijders PJ, Cstle PE, Ginecol Oncol 2006 103 1 12 7 10.1016/j.ygyno.2006.07.031 (Pubitemid 44374721)
14. Commercially available assays for multiplex detection of alpha human papillomaviruses. Poljak M, Kocjan BJ, Expert Rev Anti Infect Ther 2010 8 10 1139 62 10.1586/eri.10.104 20954880
15. Joint European Cohort Study. Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. Dillner J, Rebolj M, Birembaut P, Petry KU, Szarewski A, Munk C, de Sanjose S, Naucler P, Lloveras B, Kjaer S, Cuzick J, van Ballegooijen M, Clavel C, Iftner T, BMJ 2008 337 1754 10.1136/bmj.a1754 18852164
16. HPV testing in combination with liquid-based cytology in primary cervical screening (ARTISTIC): a randomised controlled trial. Kitchener HC, Almonte M, Thomson C, Wheeler P, Sargent A, Stoykova B, Gilham C, Baysson H, Roberts C, Dowie R, Desai M, Mather J, Bailey A, Turner A, Moss S, Peto J, Lancet Oncol 2009 10 7 672 82 10.1016/S1470-2045(09)70156-1 19540162
17. Interlaboratory reliability of Hybrid Capture 2. Castle PE, Wheeler CM, Solomon D, Schiffman M, Peyton CL, ALTS Group, Am J Clin Pathol 2004 122 2 238 45 10.1309/BA43HMCAJ26VWQH3 15323141 (Pubitemid 38971357)
18. Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. Meijer CJ, Berkhof J, Castle PE, Hesselink AT, Franco EL, Ronco G, Arbyn M, Bosch FX, Cuzick J, Dillner J, Heideman DA, Snijders PJ, Int J Cancer 2009 124 3 516 20 10.1002/ijc.24010 18973271
19. Enhanced Detection and Typing of Human Papillomavirus (HPV) DNA in Anogenital Samples with PGMY Primers and the Linear Array HPV Genotyping Test. Coutlée F, Rouleau D, Petignat P, Ghattas G, Kornegay JR, Schlag P, Boyle S, Hankins C, Vézina S, Coté P, Macleod J, Voyer H, Forest P, Walmsley S, Franco E, J Clin Microbiol 2006 44 1998 2006 10.1128/JCM.00104-06 16757590 (Pubitemid 43902145)
20. A comparison of a prototype PCR assay and hybrid capture 2 for detection of carcinogenic human papillomavirus DNA in women with equivocal or mildly abnormal papanicolaou smears. Schiffman M, Wheeler CM, Dasgupta A, Solomon D, Castle PE, ALTS Group, Am J Clin Pathol 2005 124 5 722 32 10.1309/ E067X0L1U3CY37NW 16203281 (Pubitemid 41532507)
21. A comparison of linear array and hybrid capture 2 for detection of carcinogenic human papillomavirus and cervical precancer in ASCUS-LSIL triage study. Schiffman M, Solomon D, Wheeler CM, Castle PE, Cancer Epidemiol Biomarkers Prev 2008 17 5 1248 54 10.1158/1055-9965.EPI-07-2904 18483347
22. Use of a linear array for the detection of human papillomavirus genotypes in head and neck cancer. Black CC, Bentley HA, Davis TH, Tsongalis GJ, Arch Pathol Lab Med 2010 134 12 1813 7 21128780
23. Comparison of molecular methods for detection of HPV in oral and oropharyngeal squamous cell carcinoma. Kingma DW, Allen RA, Caughron SK, Melby M, Moore WE, Gillies EM, Marlar RA, Dunn TS, Diagn Mol Pathol 2010 19 4 218 23 10.1097/PDM.0b013e3181d0cd35 21051999
24. Pilot study of a commercialized human papillomavirus (HPV) genotyping assay: comparison of HPV risk group to cytology and histology. Castle PE, Sadorra M, Garcia F, Holladay EB, Kornegay J, J Clin Microbiol 2006 44 11 3915 7 10.1128/JCM.01305-06 16971652 (Pubitemid 44737228)
25. High- throughput genotyping of high-risk HPV by the digene HPV Genotyping LQ Test using GP5+/6+-PCR and xMAP technology. Geraets DT, Heideman DA, de Koning MN, Snijders PJ, Meijer CJ, van Doorn LJ, Quint WG, J Clin Virol 2009 46 Suppl 3 21 26 20129070
26. Universal human papillomavirus genotyping by the digene HPV Genotyping RH and LQ Tests. Geraets DT, Lenselink CH, Bekkers RL, van Doorn LJ, Quint WG, Melchers WJ, J Clin Virol 2011 50 4 276 80 10.1016/j.jcv.2010.12.011 21296612
27. High genotyping concordance between the digene HPV Genotyping RH Test and the Reverse Line Blot genotyping assay on GP5+/6+-PCR products. Geraets DT, Heideman DA, de Koning MN, Snijders PJ, Meijer CJ, van Doorn LJ, Quint WG, J Clin Virol 2009 46 Suppl 3 16 20 20129069
28. Digene HPV Genotyping RH Test RUO: comparative evaluation with INNO-LiPA HPV Genotyping Extra Test for detection of 18 high-risk and probable high-risk human papillomavirus genotypes. Seme K, Lepej SZ, Lunar MM, Isci-Bes J, Planini A, Kocjan BJ, Vince A, Poljak M, J Clin Virol 2009 46 2 176 9 10.1016/j.jcv.2009.07.017 19683958
29. The measurement of observer agreement for categorical data. Landis JR, Koch GG, Biometrics 1977 33 159 174 10.2307/2529310 843571 (Pubitemid 8054849)
30. Large sample standard errors of kappa and weighted kappa. Fleiss JL, Cohen J, Everitt BS, Psychological Bulletin 1969 72 323 327
31. HPV screening for cervical cancer in rural India. Sankaranarayanan R, Nene BM, Shastri SS, Jayant K, Muwonge R, Budukh AM, Hingmire S, Malvi SG, Thorat R, Kothari A, Chinoy R, Kelkar R, Kane S, Desai S, Keskar VR, Rajeshwarkar R, Panse N, Dinshaw KA, N Engl J Med 2009 360 14 1385 94 10.1056/NEJMoa0808516 19339719
32. Human papillomavirus typing with hybrid capture II on archived liquid-based cytologic specimens: is HPV typing always reproducible? Negri G, Rigo B, Vittadello F, Egarter-Vigl E, Mian C, Am J Clin Pathol 2004 122 1 90 3 10.1309/RUDE6NRH2NGENYRR 15272535 (Pubitemid 38849877)
33. DNA extraction: an understudied and important aspect of HPV genotyping using PCR-based methods. Dunn ST, Allen RA, Wang S, Walker J, Schiffman M, J Virol Methods 2007 143 1 45 54 10.1016/j.jviromet.2007.02.006 17399803 (Pubitemid 46802824)
34. Highly effective detection of human papillomavirus 16 and 18 DNA by a testing algorithm combining broad-spectrum and type-specific PCR. van Doorn LJ, Molijn A, Kleter B, Quint W, Colau B, J Clin Microbiol 2006 44 9 3292 8 10.1128/JCM.00539-06 16954263 (Pubitemid 44413767)
35. The clinical relevance of human papillomavirus testing: relationship between analytical and clinical sensitivity. Snijders PJ, van den Brule AJ, Meijer CJ, J Pathol 2003 201 1 1 6 10.1002/path.1433 12950011 (Pubitemid 37121197)
36. PCR detection of human papillomavirus: comparison between MY09/MY11 and GP5+/GP6+ primer systems. Qu W, Jiang G, Cruz Y, Chang CJ, Ho GY, Klein RS, Burk RD, J Clin Microbiol 1997 35 6 1304 10 9163434 (Pubitemid 27216785)